世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

動脈塞栓療法市場:製品毎(塞栓剤、ガイドワイヤ)、疾患毎(がん、動脈瘤、末梢血管)、エンドユーザ毎(病院、クリニック、外来手術センタ、学術) - 2024年までの世界市場予測

Embolotherapy Market by Product (Embolic Agents (Microspheres, Detachable Coils, Pushable Coils), Guidewires), Disease (Oncology, Aneurysm, Peripheral Vascular), Procedure, End User (Hospitals, Clinics, ASC, Academia) - Global Forecast to 2024

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2019年8月US$5,650
シングルユーザライセンス
220 221

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)の動脈塞栓療法市場に関する調査レポートです。

“The embolotherapy market is projected to grow at a CAGR of 8.1% during the forecast period”

The embolotherapy market is projected to reach USD 4.9 billion by 2024 from USD 3.3 billion in 2019, at a CAGR of 8.1% from 2019 to 2024. The growth of this market is primarily driven by the rising burden of target diseases and increasing investments, funds, and grants for the development of novel products. Moreover, increasing demand for minimally invasive procedures, favorable reimbursement scenario, and new product launches in the market are further supporting the growth of the market over the forecast period. However, stringent regulatory frameworks for product commercialization and the strong market positioning of alternative treatments are expected to limit the optimal adoption of embolotherapy devices during the forecast period.

“The cancer segment, by disease indication, accounted for the largest share of the embolotherapy market in 2018”

In terms of disease indication, embolotherapy market is classified into cancer, peripheral vascular diseases, neurological diseases, urological & nephrological disorders, and gastrointestinal disorders. The high success rate and less post-operative complication rate associated with embolotherapy procedures coupled with the rising incidences of liver cancer and hepatocellular cancer are the key factors fueling the demand for embolotherapy devices for cancer disease indication. For instance, liver cancer is the fifth most common cancer in men and the ninth most common in women.

“The embolic agents segment, by product, is to register a significant growth rate owing to new product approvals”

Based on product, the embolotherapy market is broadly segmented into embolic agents and support devices. The embolic agents segment is further subsegmented into embolic coils, embolic plug systems, liquid embolic agents, microspheres, and detachable balloons. Whereas, the support devices segment includes microcatheters and guidewires. The embolic agents segment is anticipated to register the highest growth over the forecast period owing to new product approvals and launches in the segment. For instance, in 2019, Terumo received the FDA Premarket Approval (PMA) for the ‘WEB Aneurysm Embolization System.’ Moreover, in 2018, Medtronic launched OptiSphere embolization spheres in the US as well as the Concerto 3D detachable coil system in Ireland.

 “The US market, by region, commanded the largest market share in 2018”

On the basis of region, the embolotherapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The US held the major share of the global embolotherapy market in 2018. Factors such as the favorable reimbursement scenario in the US, growing target patient population (CVDs, neurovascular diseases, cancer, and uterine fibroids), increasing preference for minimally invasive procedures, new product launches and technological advancements in embolotherapy devices, and the presence of key players in the region are driving the growth of the embolotherapy market in the US.

Breakdown of supply-side primary interviews:

- By Company Type: Tier 1 - 25%, Tier 2 - 30%, and Tier 3 - 45%
- By Designation: C-level - 26%, Director-level - 30%, and Others - 44%
- By Country: North America- 34%, Europe - 26%, APAC - 23%, and RoW - 17%

The major players in the market include Boston Scientific Corporation (US), Merit Medical Systems (US), Terumo Corporation (Japan), Medtronic plc (Ireland), Johnson & Johnson (US), Stryker Corporation (US), BTG plc (UK), Penumbra, Inc. (US), Cook Medical (US), Abbott Laboratories (US), Acandis GmbH (Germany), BALT Extrusion (France), Sirtex Medical Limited (Australia), Kaneka Corporation (Japan), and Meril Life Sciences Pvt. Ltd. (India) among others.

Research Coverage

This report studies the embolotherapy market based on product, disease indication, procedure, end user, and region. The report also studies factors such as drivers, restraints, opportunities, and challenges affecting market growth. It also provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to individual growth trends, and it also forecasts the revenue of the market segments with respect to four main countries.

Key Benefits of Buying the Report

This report focuses on various levels of analysis-industry trends, market shares of top players, and company profiles, which together form basic views. It also analyzes the competitive landscape; and high-growth countries along with their respective drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.



目次

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY 22
1.5 LIMITATIONS 22
1.6 STAKEHOLDERS 23

2 RESEARCH METHODOLOGY 24
2.1 RESEARCH DATA 24
2.1.1 SECONDARY DATA 26
2.1.1.1 Key data from secondary sources 26
2.1.2 PRIMARY DATA 27
2.1.2.1 Key data from primary sources 28
2.2 MARKET SIZE ESTIMATION 30
2.2.1 PRODUCT-BASED MARKET ESTIMATION 30
2.2.2 PRIMARY RESEARCH VALIDATION 32
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 33
2.4 RESEARCH ASSUMPTIONS 34
2.5 RESEARCH LIMITATIONS 34

3 EXECUTIVE SUMMARY 35

4 PREMIUM INSIGHTS 39
4.1 EMBOLOTHERAPY: MARKET OVERVIEW 39
4.2 EMBOLOTHERAPY MARKET, BY PRODUCT 40
4.3 EMBOLOTHERAPY MARKET, BY PROCEDURE AND REGION 41
4.4 EMBOLOTHERAPY MARKET, BY DISEASE INDICATION 42
4.5 ASIA PACIFIC EMBOLOTHERAPY MARKET, BY END USER AND COUNTRY 43
4.6 GEOGRAPHIC SNAPSHOT OF THE EMBOLOTHERAPY MARKET 44

5 MARKET OVERVIEW 45
5.1 INTRODUCTION 45
5.2 MARKET DYNAMICS 45
5.2.1 DRIVERS 46
5.2.1.1 Growing target patient population 46
5.2.1.2 Rising patient preference for minimally invasive procedures 47
5.2.1.3 Funding & investments by government and private organizations 47
5.2.1.4 Technological advancements in embolotherapy devices 48
5.2.1.5 Favorable reimbursement scenario for minimally invasive surgeries 49
5.2.2 RESTRAINTS 50
5.2.2.1 Lack of sufficient evidence & unfavorable regulatory scenario 50
5.2.2.2 Strong market positioning of alternative therapies 51
5.2.3 OPPORTUNITIES 52
5.2.3.1 Growth opportunities offered by emerging markets 52
5.2.3.2 Expanding applications of embolization devices 52
5.2.4 CHALLENGES 53
5.2.4.1 Dearth of skilled surgeons 53
5.2.4.2 High costs and resulting difficulties in accessing embolization in developing countries 53

6 EMBOLOTHERAPY MARKET, BY PRODUCT 54
6.1 INTRODUCTION 55
6.2 EMBOLIC AGENTS 55
6.2.1 MICROSPHERES 57
6.2.1.1 Preference for alternative procedures limits the growth of this market segment 57
6.2.2 EMBOLIC COILS 59
6.2.2.1 Detachable coils 61
6.2.2.1.1 Detachable coils can be retracted and redeployed a number of times until satisfactory placement is reached, which is a key advantage of this product segment 61
6.2.2.2 Pushable coils 62
6.2.2.2.1 Use of pushable coils increases the risk of non-target vascular blockages, thereby hampering their use in various applications 62
6.2.3 LIQUID EMBOLIC AGENTS 63
6.2.3.1 Significant adoption of embolic coils due to their procedural benefits over liquid embolic agents is expected to restrict market growth 63
6.2.4 EMBOLIC PLUG SYSTEMS 64
6.2.4.1 Procedural advantages delivered by vascular plugs such as a significantly shorter occlusion time and recanalization rate are the key factors leading to their increased adoption 64
6.2.5 DETACHABLE BALLOONS 65
6.2.5.1 Adverse events associated with the use of detachable balloons such as balloon rupture, failure, or shrinkage may limit the utilization of this embolic device 65
6.3 SUPPORT DEVICES 66
6.3.1 MICROCATHETERS 67
6.3.1.1 Advancements and regulatory approvals in microcatheter technologies are expected to result in their wider adoption 67
6.3.2 GUIDEWIRES 68
6.3.2.1 Rising adoption of guidewires among medical professionals owing to their procedural benefits is expected to drive market growth 68

7 EMBOLOTHERAPY MARKET, BY DISEASE INDICATION 70
7.1 INTRODUCTION 71
7.2 CANCER 71
7.2.1 LIVER CANCER 73
7.2.1.1 Rising prevalence of liver cancer is projected to fuel segment growth 73
7.2.2 KIDNEY CANCER 74
7.2.2.1 The wide adoption of preoperative kidney tumor embolization in the treatment of kidney cancer is driving market growth 74
7.2.3 OTHER CANCERS 75
7.2.3.1 Increasing clinical research to check the effectiveness of embolization for cancer treatment to drive market growth 75
7.3 PERIPHERAL VASCULAR DISEASE 76
7.3.1 RISING ADOPTION OF VASCULAR PLUGS IS A KEY DRIVING FACTOR FOR THE MARKET 76
7.4 NEUROLOGICAL DISEASES 77
7.4.1 CEREBRAL ANEURYSM 78
7.4.1.1 Limited availability of reimbursements across major markets may hinder market growth 78
7.4.2 ARTERIOVENOUS MALFORMATION AND FISTULAS 79
7.4.2.1 Side effects associated with AVM embolization procedures may restrict market growth to a certain extent 79
7.5 UROLOGICAL & NEPHROLOGICAL DISORDERS 80
7.5.1 EMBOLIC AGENTS ARE USED TO TREAT UTERINE FIBROIDS, AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, AND BENIGN PROSTATIC HYPERPLASIA 80
7.6 GASTROINTESTINAL DISORDERS 81
7.6.1 EMBOLIZATION IS A WIDELY ADOPTED PROCEDURE USED TO TREAT LGIB AND UGIB 81

8 EMBOLOTHERAPY MARKET, BY PROCEDURE 83
8.1 INTRODUCTION 84
8.2 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE) 85
8.2.1 TRANSCATHETER ARTERIAL EMBOLIZATION DOMINATES THE EMBOLOTHERAPY MARKET DUE TO THE INCREASING INCIDENCE OF UTERINE FIBROIDS & VASCULAR LESIONS 85
8.3 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION (TARE)/SELECTIVE INTERNAL RADIATION THERAPY (SIRT) 86
8.3.1 BETTER CLINICAL OUTCOMES & INCREASED CANCER SURVIVAL RATE ARE SUPPORTING THE GROWTH OF THIS SEGMENT 86
8.4 TRANSARTERIAL CHEMOEMBOLIZATION (TACE) 87
8.4.1 TACE CAN BE USED TO TREAT TUMORS THAT ARE RELATIVELY LARGER IN SIZE, WHICH CANNOT BE EASILY TREATED BY TUMOR ABLATION 87

9 EMBOLOTHERAPY MARKET, BY END USER 89
9.1 INTRODUCTION 90
9.2 HOSPITALS AND CLINICS 90
9.3 AMBULATORY SURGERY CENTERS 91
9.4 OTHER END USERS 92

10 EMBOLOTHERAPY MARKET, BY REGION 94
10.1 INTRODUCTION 95
10.2 NORTH AMERICA 95
10.2.1 US 102
10.2.1.1 The US dominates the global embolotherapy market in 2018 due to the large R&D investments in the country 102
10.2.2 CANADA 106
10.2.2.1 High burden of cancer to support market growth 106
10.3 EUROPE 110
10.3.1 GERMANY 117
10.3.1.1 Germany is the fastest-growing market in Europe 117
10.3.2 UK 121
10.3.2.1 Increasing incidence of target health conditions coupled with the rising geriatric population to drive market growth 121
10.3.3 FRANCE 125
10.3.3.1 Government initiatives to raise awareness about embolotherapy will increase the adoption of embolization procedures in the country 125
10.3.4 REST OF EUROPE 129
10.4 ASIA PACIFIC 133
10.4.1 JAPAN 140
10.4.1.1 Growing geriatric population and the increasing R&D investments in the country are the major factors driving market growth 140
10.4.2 CHINA 144
10.4.2.1 China to register the highest growth in the APAC embolotherapy market due to the growing target patient population 144
10.4.3 INDIA 148
10.4.3.1 Ongoing modernization and expansion of healthcare infrastructure and growing medical tourism to support market growth 148
10.4.4 REST OF ASIA PACIFIC 151
10.5 LATIN AMERICA 155
10.5.1 BRAZIL 161
10.5.1.1 Increasing incidence of hepatocellular carcinoma and cerebral aneurysm to drive the adoption of embolization products 161
10.5.2 REST OF LATIN AMERICA 164
10.6 MIDDLE EAST & AFRICA 168
-
11 COMPETITIVE LANDSCAPE 173
11.1 INTRODUCTION 173
11.2 MARKET SHARE ANALYSIS 174
11.2.1 MARKET SHARE ANALYSIS FOR MICROSPHERES (2018) 174
11.2.2 MARKET SHARE ANALYSIS FOR EMBOLIZATION COILS (2018) 175
11.3 COMPETITIVE SITUATION AND TRENDS 176
11.4 COMPETITIVE LEADERSHIP MAPPING 178
11.5 VENDOR INCLUSION CRITERIA 178
11.6 VENDOR DIVE 178
11.6.1 VISIONARY LEADERS 178
11.6.2 INNOVATORS 178
11.6.3 DYNAMIC DIFFERENTIATORS 178
11.6.4 EMERGING PLAYERS 179

12 COMPANY PROFILES 180
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 ABBOTT LABORATORIES 180
12.2 ACANDIS GMBH 182
12.3 BALT EXTRUSION 183
12.4 BOSTON SCIENTIFIC CORPORATION 185
12.5 BTG PLC 187
12.6 COOK MEDICAL 190
12.7 JOHNSON & JOHNSON 191
12.8 KANEKA CORPORATION 193
12.9 MEDTRONIC PLC 195
12.10 MERIL LIFE SCIENCES PVT., LTD. 197
12.11 MERIT MEDICAL SYSTEMS 198
12.12 PENUMBRA, INC. 201
12.13 SIRTEX MEDICAL LIMITED 203
12.14 STRYKER CORPORATION 204
12.15 TERUMO CORPORATION 206
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX 210
13.1 DISCUSSION GUIDE 210
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 216
13.3 AVAILABLE CUSTOMIZATIONS 218
13.4 RELATED REPORTS 218
13.5 AUTHOR DETAILS 219

 

LIST OF TABLES

TABLE 1 PRIMARY LIVER CANCER INCIDENCE AMONG MEN AND WOMEN (2005 VS 2030) 46
TABLE 2 GERIATRIC POPULATION, BY REGION, 2015 VS 2030 47
TABLE 3 MEDICAL REIMBURSEMENT CPT CODES FOR EMBOLIZATION PROCEDURES IN THE US (EFFECTIVE FROM JANUARY 2019) 49
TABLE 4 MEDICAL REIMBURSEMENT MS-DRG CODES FOR EMBOLIZATION PROCEDURES IN THE US (EFFECTIVE FROM JANUARY 2019) 50
TABLE 5 EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 55
TABLE 6 EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 56
TABLE 7 EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY REGION,
2017-2024 (USD MILLION) 56
TABLE 8 EMBOLIC AGENTS, BY TYPE 57
TABLE 9 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY REGION,
2017-2024 (USD MILLION) 59
TABLE 10 EMBOLIC COILS OFFERED BY MAJOR MARKET PLAYERS 60
TABLE 11 EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 60
TABLE 12 EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY REGION,
2017-2024 (USD MILLION) 61
TABLE 13 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY REGION,
2017-2024 (USD MILLION) 62
TABLE 14 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY REGION,
2017-2024 (USD MILLION) 63
TABLE 15 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY REGION,
2017-2024 (USD MILLION) 64
TABLE 16 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY REGION,
2017-2024 (USD MILLION) 65
TABLE 17 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY REGION,
2017-2024 (USD MILLION) 66
TABLE 18 EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2017-2024 (USD MILLION) 66
TABLE 19 EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY REGION,
2017-2024 (USD MILLION) 67
TABLE 20 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY REGION,
2017-2024 (USD MILLION) 68
TABLE 21 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY REGION,
2017-2024 (USD MILLION) 69
TABLE 22 EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 71
TABLE 23 EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, 2017-2024 72
TABLE 24 EMBOLOTHERAPY MARKET FOR CANCER, BY REGION, 2017-2024 72
TABLE 25 EMBOLOTHERAPY MARKET FOR LIVER CANCER, BY REGION,
2017-2024 (USD MILLION) 73
TABLE 26 EMBOLOTHERAPY MARKET FOR KIDNEY CANCER, BY REGION,
2017-2024 (USD MILLION) 74
TABLE 27 EMBOLOTHERAPY MARKET FOR OTHER CANCERS, BY REGION,
2017-2024 (USD MILLION) 75
TABLE 28 EMBOLOTHERAPY MARKET FOR PERIPHERAL VASCULAR DISEASES, BY REGION, 2017-2024 (USD MILLION) 76
TABLE 29 EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE,
2017-2024 77
TABLE 30 EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY REGION,
2017-2024 (USD MILLION) 78
TABLE 31 EMBOLOTHERAPY MARKET FOR CEREBRAL ANEURYSMS, BY REGION,
2017-2024 (USD MILLION) 79
TABLE 32 EMBOLOTHERAPY MARKET FOR ARTERIOVENOUS MALFORMATION & FISTULAS,
BY REGION, 2017-2024 (USD MILLION) 80
TABLE 33 EMBOLOTHERAPY MARKET FOR UROLOGICAL & NEPHROLOGICAL DISEASES,
BY REGION, 2017-2024 (USD MILLION) 81
TABLE 34 EMBOLOTHERAPY MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2017-2024 (USD MILLION) 82
TABLE 35 EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION) 84
TABLE 36 TRANSCATHETER ARTERIAL EMBOLIZATION MARKET, BY REGION,
2017-2024 (USD MILLION) 86
TABLE 37 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION MARKET, BY REGION,
2017-2024 (USD MILLION) 87
TABLE 38 TRANSARTERIAL CHEMOEMBOLIZATION MARKET, BY REGION, 2017-2024 88
TABLE 39 EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION) 90
TABLE 40 EMBOLOTHERAPY MARKET FOR HOSPITALS AND CLINICS, BY REGION,
2017-2024 (USD MILLION) 91
TABLE 41 EMBOLOTHERAPY MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2017-2024 (USD MILLION) 92
TABLE 42 EMBOLOTHERAPY MARKET FOR OTHER END USERS, BY REGION,
2017-2024 (USD MILLION) 93
TABLE 43 EMBOLOTHERAPY MARKET, BY REGION, 2017-2024 (USD MILLION) 95
TABLE 44 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY COUNTRY,
2017-2024 (USD MILLION) 97
TABLE 45 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 97
TABLE 46 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS,
BY TYPE, 2017-2024 (USD MILLION) 98
TABLE 47 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS,
BY TYPE, 2017-2024 (USD MILLION) 98
TABLE 48 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES,
BY TYPE, 2017-2024 (USD MILLION) 99
TABLE 49 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 99
TABLE 50 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 100
TABLE 51 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES,
BY TYPE, 2017-2024 (USD MILLION) 100
TABLE 52 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2017-2024 (USD MILLION) 101
TABLE 53 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY END USER,
2017-2024 (USD MILLION) 101
TABLE 54 MEDICARE REIMBURSEMENT FOR TRANSCATHETER EMBOLIZATION OR OCCLUSION SERVICES: 2019 102
TABLE 55 US: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 103
TABLE 56 US: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 103
TABLE 57 US: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 104
TABLE 58 US: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2017-2024 (USD MILLION) 104
TABLE 59 US: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 105
TABLE 60 US: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION) 105
TABLE 61 US: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION) 106
TABLE 62 CANADA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 107
TABLE 63 CANADA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 107
TABLE 64 CANADA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 108
TABLE 65 CANADA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2017-2024 (USD MILLION) 108
TABLE 66 CANADA: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 109
TABLE 67 CANADA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION) 109
TABLE 68 CANADA: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION) 110
TABLE 69 EUROPE: EMBOLOTHERAPY MARKET, BY COUNTRY, 2017-2024 (USD MILLION) 112
TABLE 70 EUROPE: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 112
TABLE 71 EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 113
TABLE 72 EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 113
TABLE 73 EUROPE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2017-2024 (USD MILLION) 114
TABLE 74 EUROPE: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 114
TABLE 75 EUROPE: EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 115
TABLE 76 EUROPE: EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, 2017-2024 (USD MILLION) 115
TABLE 77 EUROPE: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION) 116
TABLE 78 EUROPE: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION) 116
TABLE 79 GERMANY: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 117
TABLE 80 GERMANY: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 118
TABLE 81 GERMANY: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 118
TABLE 82 GERMANY: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
 2017-2024 (USD MILLION) 119
TABLE 83 GERMANY: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 119
TABLE 84 GERMANY: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2017-2024 (USD MILLION) 120
TABLE 85 GERMANY: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION) 120
TABLE 86 UK: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 121
TABLE 87 UK: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 122
TABLE 88 UK: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 122
TABLE 89 UK: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2017-2024 (USD MILLION) 123
TABLE 90 UK: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 123
TABLE 91 UK: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION) 124
TABLE 92 UK: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION) 124
TABLE 93 FRANCE: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 125
TABLE 94 FRANCE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 126
TABLE 95 FRANCE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 126
TABLE 96 FRANCE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2017-2024 (USD MILLION) 127
TABLE 97 FRANCE: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 127
TABLE 98 FRANCE: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION) 128
TABLE 99 FRANCE: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION) 128
TABLE 100 ROE: HEALTH EXPENDITURE, BY COUNTRY (2017) 129
TABLE 101 AGING POPULATION (% SHARE OF THE TOTAL POPULATION), BY COUNTRY,
2015 VS. 2030 (IN MILLION) 129
TABLE 102 CANCER INCIDENCE, BY COUNTRY, 2018 130
TABLE 103 ROE: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 130
TABLE 104 ROE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 131
TABLE 105 ROE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 131
TABLE 106 ROE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2017-2024 (USD MILLION) 132
TABLE 107 ROE: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 132
TABLE 108 ROE: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION) 133
TABLE 109 ROE: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION) 133
TABLE 110 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY COUNTRY,
2017-2024 (USD MILLION) 135
TABLE 111 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 135
TABLE 112 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 136
TABLE 113 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 136
TABLE 114 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2017-2024 (USD MILLION) 137
TABLE 115 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 137
TABLE 116 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 138
TABLE 117 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES,
BY TYPE, 2017-2024 (USD MILLION) 138
TABLE 118 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2017-2024 (USD MILLION) 139
TABLE 119 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY END USER,
2017-2024 (USD MILLION) 139
TABLE 120 JAPAN: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 140
TABLE 121 JAPAN: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 141
TABLE 122 JAPAN: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 141
TABLE 123 JAPAN: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2017-2024 (USD MILLION) 142
TABLE 124 JAPAN: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 142
TABLE 125 JAPAN: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION) 143
TABLE 126 JAPAN: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION) 143
TABLE 127 CHINA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 144
TABLE 128 CHINA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 145
TABLE 129 CHINA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 145
TABLE 130 CHINA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2017-2024 (USD MILLION) 146
TABLE 131 CHINA: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 146
TABLE 132 CHINA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION) 147
TABLE 133 CHINA: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION) 147
TABLE 134 INDIA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 148
TABLE 135 INDIA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 149
TABLE 136 INDIA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 149
TABLE 137 INDIA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2017-2024 (USD MILLION) 150
TABLE 138 INDIA: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 150
TABLE 139 INDIA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION) 151
TABLE 140 INDIA: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION) 151
TABLE 141 ROAPAC: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 152
TABLE 142 ROAPAC: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 152
TABLE 143 ROAPAC: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 153
TABLE 144 ROAPAC: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2017-2024 (USD MILLION) 153
TABLE 145 ROAPAC: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 154
TABLE 146 ROAPAC: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION) 154
TABLE 147 ROAPAC: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION) 155
TABLE 148 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY COUNTRY,
2017-2024 (USD MILLION) 156
TABLE 149 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 156
TABLE 150 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS,
BY TYPE, 2017-2024 (USD MILLION) 157
TABLE 151 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 157
TABLE 152 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2017-2024 (USD MILLION) 158
TABLE 153 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 158
TABLE 154 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE,
2017-2024 (USD MILLION) 159
TABLE 155 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES,
BY TYPE, 2017-2024 (USD MILLION) 159
TABLE 156 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2017-2024 (USD MILLION) 160
TABLE 157 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY END USER,
2017-2024 (USD MILLION) 160
TABLE 158 BRAZIL: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 161
TABLE 159 BRAZIL: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 162
TABLE 160 BRAZIL: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 162
TABLE 161 BRAZIL: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2017-2024 (USD MILLION) 163
TABLE 162 BRAZIL: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 163
TABLE 163 BRAZIL: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION) 164
TABLE 164 BRAZIL: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION) 164
TABLE 165 ROLA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2017-2024 (USD MILLION) 165
TABLE 166 ROLA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2017-2024 (USD MILLION) 165
TABLE 167 ROLA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2017-2024 (USD MILLION) 166
TABLE 168 ROLA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2017-2024 (USD MILLION) 166
TABLE 169 ROLA: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION,
2017-2024 (USD MILLION) 167
TABLE 170 ROLA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2017-2024 (USD MILLION) 167
TABLE 171 ROLA: EMBOLOTHERAPY MARKET, BY END USER, 2017-2024 (USD MILLION) 168
TABLE 172 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2017-2024 (USD MILLION) 168
TABLE 173 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS,
BY TYPE, 2017-2024 (USD MILLION) 169
TABLE 174 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS,
BY TYPE, 2017-2024 (USD MILLION) 169
TABLE 175 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES,
BY TYPE, 2017-2024 (USD MILLION) 170
TABLE 176 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY DISEASE INDICATION, 2017-2024 (USD MILLION) 170
TABLE 177 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION) 171
TABLE 178 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, 2017-2024 (USD MILLION) 171
TABLE 179 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2017-2024 (USD MILLION) 172
TABLE 180 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY END USER,
2017-2024 (USD MILLION) 172
TABLE 181 PRODUCT LAUNCHES AND APPROVALS 176
TABLE 182 COLLABORATIONS 176
TABLE 183 EXPANSIONS 177
TABLE 184 ACQUISITIONS 177

 

LIST OF FIGURES

FIGURE 1 EMBOLOTHERAPY MARKET: RESEARCH METHODOLOGY STEPS 24
FIGURE 2 RESEARCH DESIGN 25
FIGURE 3 BREAKDOWN OF PRIMARIES: EMBOLOTHERAPY MARKET 28
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 29
FIGURE 5 BOTTOM-UP APPROACH MARKET SIZE ESTIMATION: EMBOLOTHERAPY MARKET 31
FIGURE 6 TOP-DOWN APPROACH MARKET SIZE ESTIMATION: EMBOLOTHERAPY MARKET 31
FIGURE 7 DATA TRIANGULATION METHODOLOGY 33
FIGURE 8 EMBOLOTHERAPY MARKET, BY PRODUCT, 2019-2024 (USD MILLION) 35
FIGURE 9 EMBOLOTHERAPY MARKET SHARE, BY DISEASE INDICATION, 2019 VS. 2024 36
FIGURE 10 EMBOLOTHERAPY MARKET SHARE, BY PROCEDURE, 2019-2024 (USD MILLION) 37
FIGURE 11 EMBOLOTHERAPY MARKET, BY END USER, 2019-2024 (USD MILLION) 37
FIGURE 12 EMBOLOTHERAPY MARKET, BY REGION: GEOGRAPHICAL SNAPSHOT 38
FIGURE 13 RISING INCIDENCE OF CHRONIC DISEASES IS DRIVING THE GROWTH OF THE EMBOLOTHERAPY MARKET ACROSS THE GLOBE 39
FIGURE 14 MICROSPHERES SEGMENT WILL WITNESS HIGH GROWTH IN THE MARKET 40
FIGURE 15 TRANSCATHETER ARTERIAL EMBOLIZATION SEGMENT TO DOMINATE THE NORTH AMERICAN MARKET IN 2019 41
FIGURE 16 CANCER SEGMENT TO DOMINATE THE EMBOLOTHERAPY MARKET DURING THE FORECAST PERIOD 42
FIGURE 17 AMBULATORY SURGERY CENTERS SEGMENT WILL REGISTER THE HIGHEST CAGR IN ASIA PACIFIC 43
FIGURE 18 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 44
FIGURE 19 EMBOLOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 45
FIGURE 20 NORTH AMERICA: EMBOLOTHERAPY MARKET SNAPSHOT 96
FIGURE 21 EUROPE: EMBOLOTHERAPY MARKET SNAPSHOT 111
FIGURE 22 ASIA PACIFIC: EMBOLOTHERAPY MARKET SNAPSHOT 134
FIGURE 23 KEY DEVELOPMENTS IN THE EMBOLOTHERAPY MARKET FROM 2015 TO 2019 173
FIGURE 24 BTG PLC ACCOUNTED FOR THE LARGEST SHARE OF THE MICROSPHERES MARKET IN 2018 174
FIGURE 25 STRYKER HELD THE LEADING POSITION OF THE EMBOLIZATION COILS
MARKET IN 2018 175
FIGURE 26 EMBOLOTHERAPY MARKET:GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2018 179
FIGURE 27 ABBOTT LABORATORIES: COMPANY SNAPSHOT 180
FIGURE 28 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 185
FIGURE 29 BTG PLC: COMPANY SNAPSHOT 187
FIGURE 30 JOHNSON & JOHNSON: COMPANY SNAPSHOT 191
FIGURE 31 KANEKA CORPORATION: COMPANY SNAPSHOT 193
FIGURE 32 MEDTRONIC PLC: COMPANY SNAPSHOT 195
FIGURE 33 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT 198
FIGURE 34 PENUMBRA, INC.: COMPANY SNAPSHOT 201
FIGURE 35 SIRTEX MEDICAL LIMITED: COMPANY SNAPSHOT 203
FIGURE 36 STRYKER CORPORATION: COMPANY SNAPSHOT 204
FIGURE 37 TERUMO CORPORATION: COMPANY SNAPSHOT 206

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る